Bank of America just raised its EUR/USD forecast
On Friday, Goldman Sachs reiterated its Buy rating on Cameco Corporation (NYSE:CCJ), which has seen an impressive 130% gain year-to-date. The stock’s momentum comes amid news that President Trump is expected to sign an executive order aimed at bolstering the nuclear energy industry. With an average analyst consensus leaning strongly toward Buy and a market capitalization of $6.79 billion, Cameco has positioned itself as a key player in the sector. The order, anticipated to be signed today, is designed to improve regulatory processes and strengthen supply chains for the sector. According to InvestingPro, there are 15+ additional investment insights available for Cameco that could help investors make more informed decisions.
The executive order, as reported by Reuters on May 22, is expected to invoke the Defense Production Act to address the United States’ reliance on uranium imports from China and Russia. It will likely streamline the permitting and siting of new nuclear plants and direct the Department of Energy and the Department of Defense to locate federal lands suitable for nuclear deployments. This move aims to accelerate the construction process for nuclear facilities.
The order also encourages the use of the Loan Program Office for loan guarantees and direct loans to expand the nation’s nuclear capacity. Goldman Sachs analysts believe that Cameco Corporation, as a uranium producer, stands to gain from this initiative. An increase in nuclear generating capacity is projected to boost the demand for physical uranium and conversion services.
Cameco’s 49% stake in Westinghouse is also seen as a potential beneficiary since Westinghouse has significant involvement in new reactor builds and operations. The construction of new nuclear plants, particularly if Westinghouse’s AP1000 technology is selected, could provide an uplift to this segment of the company.
Additionally, small modular reactors (SMRs) could see advantages from the executive order, especially if there are further allocations for loan dollars specifically earmarked for SMRs. The push for SMRs may extend to both civilian and defense power applications, presenting another growth opportunity for the industry.
Goldman Sachs maintains a Neutral rating on SMR but notes the long-term prospects for growing demand and faster deployment of nuclear technology are positive. The firm’s outlook on the nuclear sector remains constructive, with expectations of increased demand for fuel and services in the upstream part of the value chain. For investors seeking deeper insights, InvestingPro offers comprehensive analysis through its Pro Research Report, which provides detailed financial health metrics and expert analysis on Cameco and 1,400+ other top stocks, helping investors make more informed decisions in this evolving market landscape.
In other recent news, Oklo Inc. reported its first-quarter 2025 earnings, revealing an earnings per share (EPS) of -$0.07, slightly surpassing the forecast of -$0.08. The company also disclosed an operating loss of approximately $17.9 million, while continuing to advance its Aurora Powerhouse project at the Idaho National Laboratory. Oklo is on track to submit its combined license application to the U.S. Nuclear Regulatory Commission by the end of 2025, with plans to deploy its first commercial power plant by late 2027. Analyst Daniel Ives from Wedbush upgraded Oklo’s price target to $55, citing the company’s strategic positioning in the nuclear energy sector and its potential growth in the small modular reactor space. Meanwhile, BTIG and Citi maintained a Neutral rating on Oklo shares, with Citi setting a price target of $30. Oklo’s expansion efforts include the development of its Atomic Alchemy division and plans to generate its first revenues from this venture by 2026. Despite being in a pre-revenue stage, Oklo is strategically positioning itself to capitalize on the growing demand for nuclear energy solutions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.